GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
C4809 Lorglumide (sodium salt)Summary: nonpeptidic antagonist of the CCK A receptor
-
B7046 A-71623Summary: CCK1 agonist
-
B5058 CCK Octapeptide, non-sulfatedSummary: Non-sulfated form of the C-terminal octapeptide of CCK
-
B5121 Proglumide sodium saltSummary: Non-selective cholecystokinin (CCK) antagonist
-
B6965 SR 27897Summary: CCK1 receptor antagonist